Abbott Laboratories has established a distinctive operational blueprint for artificial intelligence deployment within the healthcare and medical technology sectors. Rather than treating emerging technology as a speculative end in itself, Abbott anchors every algorithmic, generative, and agentic capability directly to its core corporate mission of helping individuals live healthier, fuller lives. Under the leadership of Chief Information Officer and Senior Vice President of Bu

This Week in European HealthTech, MedTech and Health AI: 31st July 2026. Here is a breakdown of the major developments driving the European HealthTech ecosystem right now:

The rapid expansion of screenless wearables has positioned smart rings as a primary form factor for continuous, unobtrusive biometric monitoring. Market leader Oura Health has long established the functional benchmark for ring-based photoplethysmography (PPG), circadian rhythm tracking, and daily recovery analysis. However, the emergence of challengers such as the British-designed Leep Ring, developed by Leep Health Ltd, raises a fundamental architectural and strategic questi

The trajectory of artificial intelligence (AI) in healthcare reflects a transformation from rigid, symbolic logic systems to statistical deep learning architectures, culminating in self-reasoning, multimodal foundation models. This technological maturation has not occurred in isolation; rather, it has been driven by the co-evolution of algorithmic breakthroughs, hardware acceleration, regulatory frameworks, and clinical reimbursement structures.

The adoption and integration of digital health technologies (DHTs), including digital therapeutics (DTx), remote patient monitoring (RPM) platforms, and artificial intelligence (AI)-driven diagnostics, across European healthcare systems present a fragmented landscape. While market access for traditional medical devices in the European Union relies on unified regulatory standards under the European Medical Devices Regulation (MDR), the pathways governing Health Technology Asse

The Series B proceeds are primarily dedicated to constructing an in-house specialised AI imaging laboratory housing Qureight’s proprietary 3D chest imaging foundation model. This technological development marks a shift from task-specific narrow AI models toward generalised spatial representations, drastically reducing both the data volume and the development time required to deploy predictive models in new therapeutic indications. Consequently, Qureight is extending its estab

Nervecentre's strategic ambitions extend beyond acute hospital walls. The vendor seeks to leverage its cloud-native, multi-tenant platform to deliver a regional EPR capable of orchestrating workflows across primary, community, and acute care settings. Evaluating the probability of success for this cross-continuum expansion requires examining Nervecentre’s market momentum, technical architecture and regional alignment against the structural, commercial and technical realities

The global artificial intelligence ecosystem is undergoing a fundamental structural transition. For the past decade, AI development focused primarily on software architectures, cloud computing infrastructure, and foundation model capabilities accessible via traditional visual user interfaces. However, the inherent constraints of modern mobile operating systems, namely application sandboxing, restricted background contextual access and touch-centric interaction paradigms, have

The primary client profile for Nelson Advisors comprises clinically originated or founder-led enterprises generating annual revenues between €5 Million and €50 Million, operating EBITDA from €1 Million to €10 Million, and maintaining head counts of 20 to 250 personnel. These organisations typically possess established, scalable technologies but lack in-house corporate development infrastructure to navigate institutional M&A processes, cross-border regulatory hurdles, and comp

The proposed sale of System C Healthcare by CVC Capital Partners, currently facilitated by the corporate finance advisory firm Arma Partners, marks a defining transaction in the mid-decade consolidation of the United Kingdom’s health and social care technology sectors. The asset, held under the parent entity Asclepius Topco Limited, has undergone a fundamental transformation since its acquisition from Symphony Technology Group in February 2021.

IBM's Watson was once heralded as the future of healthcare - what went wrong? Exec Summary: IBM's Watson was once heralded as the future of healthcare. In 2011, the Jeopardy!-winning supercomputer was announced as a new tool for doctors and researchers, capable of analyzing massive amounts of data to help diagnose diseases, develop new treatments, and improve patient care. But in recent years, Watson's promise has fallen short of expectations. The technology has been slow to